Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Unit price / market price
-
$0.9057
-
Total 13F principal
-
$505,163,049
-
Principal change
-
+$29,721,675
-
Total reported value
-
$458,227,307
-
Number of holders
-
47
-
Value change
-
+$27,473,180
-
Number of buys
-
20
-
Number of sells
-
21
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q3 2020
As of 30 Sep 2020 LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 had 47 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $505,163,049 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included STEELHEAD PARTNERS LLC, CANYON CAPITAL ADVISORS LLC, ADVENT CAPITAL MANAGEMENT /DE/, UBS ASSET MANAGEMENT AMERICAS INC, WOLVERINE ASSET MANAGEMENT LLC, Davidson Kempner Capital Management LP, LAZARD ASSET MANAGEMENT LLC, OAKTREE CAPITAL MANAGEMENT LP, Nuveen Asset Management, LLC, and GOLDMAN SACHS GROUP INC.
This table shows 47 bond principal holders of the security as of 30 Sep 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.